In a sector note on U.S. Medical Supplies and Devices, UBS initiated coverage of Tandem Diabetes with a Neutral rating and $45 price target. The firm has low conviction and limited visibility into upside potential to consensus estimates with competition and a dwindling competitor conversion opportunity in the U.S. driving sustained headwinds, the analyst tells investors in a research note. The firm is modeling an 11.1% sales CAGR for the next five years vs. what was a nearly 50% sales CAGR delivered over the prior five years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TNDM:
- Tandem Diabetes initiated with a Neutral at UBS
- Tandem Diabetes announces NEJM publication of study on t:slim X2 insulin pump
- Tandem pairing with Abbott sensors can be ‘big deal,’ says Lake Street
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes price target lowered to $74 from $80 at Craig-Hallum